[1]刘克学.铝碳酸镁联合兰索拉唑治疗幽门螺旋杆菌相关性胃溃疡的临床疗效及安全性[J].医学信息,2023,36(18):140-143.[doi:10.3969/j.issn.1006-1959.2023.18.027]
　LIU Ke-xue.Clinical Efficacy and Safety of Hydrotalcite Combined with Lansoprazole in the Treatment of Helicobacter Pylori-associated Gastric Ulcer[J].Journal of Medical Information,2023,36(18):140-143.[doi:10.3969/j.issn.1006-1959.2023.18.027]
点击复制

铝碳酸镁联合兰索拉唑治疗幽门螺旋杆菌相关性胃溃疡的临床疗效及安全性()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年18期
页码:
140-143
栏目:
药物与临床
出版日期:
2023-09-15

文章信息/Info

Title:
Clinical Efficacy and Safety of Hydrotalcite Combined with Lansoprazole in the Treatment of Helicobacter Pylori-associated Gastric Ulcer
文章编号:
1006-1959（2023）18-0140-04
作者:
刘克学
（泰和县中医院急诊科，江西 泰和 343799）
Author(s):
LIU Ke-xue
(Emergency Department of Taihe County Hospital of Traditional Chinese Medicine,Taihe 343799,Jiangxi,China)
关键词:
幽门螺旋杆菌; 胃溃疡; 铝碳酸镁; 兰索拉唑
Keywords:
Helicobacter pylori; Gastric ulcer; Hydrotalcite; Lansoprazole
分类号:
R573.1
DOI:
10.3969/j.issn.1006-1959.2023.18.027
文献标志码:
A
摘要:
目的 研究铝碳酸镁联合兰索拉唑治疗幽门螺旋杆菌（Hp）相关性胃溃疡（GU）的临床疗效与安全性。方法 选取2021年4月-2022年4月泰和县中医院收治的62例Hp相关性GU病例，按照随机数字表法分为对照组（31例）与观察组（31例）。两组均应用Hp三联疗法，在此基础上，对照组给予兰索拉唑治疗，观察组采用铝碳酸镁联合兰索拉唑治疗，比较两组临床疗效、Hp根除率、溃疡直径、实验室指标[白细胞介素2（IL-2）、白细胞介素6（IL-6）]、用药安全性、消化性溃疡量表（QLICD-PU）评分、溃疡复发率。结果 观察组总有效率高于对照组（P＜0.05）；两组治疗后溃疡直径均小于治疗前，且观察组溃疡直径小于对照组（P＜0.05）；观察组Hp根除率高于对照组（P＜0.05）；两组治疗后IL-2、IL-6水平均低于治疗前，且观察组低于对照组（P＜0.05）；两组不良反应发生率比较，差异无统计学意义（P＞0.05）；两组治疗后QLICD-PU评分（生理功能、心理功能、社会功能、特异模块）均高于治疗前，且观察组QLICD-PU评分高于对照组（P＜0.05）；观察组溃疡复发率低于对照组（P＜0.05）。结论 铝碳酸镁联合兰索拉唑治疗Hp相关性GU疗效肯定，可提高Hp根除率，促进患者溃疡愈合，下调炎性指标，降低复发率，改善患者生活质量，安全性良好。
Abstract:
Objective To study the clinical efficacy and safety of hydrotalcite combined with lansoprazole in the treatment of Helicobacter pylori(Hp)-associated gastric ulcer (GU).Methods A total of 62 patients of Hp-related GU admitted to Taihe County Hospital of Traditional Chinese Medicine from April 2021 to April 2022 were selected and divided into control group (31 patients) and observation group (31 patients) according to the random number table method. Both groups were treated with Hp triple therapy. On this basis, the control group was treated with lansoprazole, and the observation group was treated with hydrotalcite combined with lansoprazole. The clinical efficacy, Hp eradication rate, ulcer diameter, laboratory indexes [interleukin-2 (IL-2), interleukin-6 (IL-6)], medication safety, peptic ulcer scale (QLICD-PU) score, ulcer recurrence rate were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group (P<0.05). After treatment, the ulcer diameter of the two groups was smaller than that before treatment, and the ulcer diameter of the observation group was smaller than that of the control group (P<0.05). The eradication rate of Hp in the observation group was higher than that in the control group (P<0.05). The levels of IL-2 and IL-6 in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). The QLICD-PU scores (physiological function, psychological function, social function, specific module) of the two groups after treatment were higher than those before treatment, and the QLICD-PU scores of the observation group after treatment were higher than those of the control group (P<0.05). The recurrence rate of ulcer in the observation group was lower than that in the control group (P<0.05).Conclusion Hydrotalcite combined with lansoprazole is effective in the treatment of Hp-related GU, which can improve the eradication rate of Hp, promote ulcer healing, down-regulate inflammatory indicators, reduce the recurrence rate, improve the quality of life of patients, and has good safety.

参考文献/References:

[1]沈曙光,高永喜,张锐,等.不同方案治疗幽门螺杆菌阳性消化性溃疡效果观察[J].人民军医,2021,64(11):1089-1092.[2]Khatoon J,Prasad KN,Prakash Rai R,et al.Association of heterogenicity of Helicobacter pylori cag pathogenicity island with peptic ulcer diseases and gastric cancer[J].Br J Biomed Sci,2017,74(3):121-126.[3]陈晓艳,李青.铝碳酸镁联合艾司奥美拉唑治疗胃溃疡伴出血患者的临床研究[J].中国临床药理学杂志,2021,37(4):370-373.[4]吴贤发.奥美拉唑与兰索拉唑及泮托拉唑治疗胃炎胃溃疡的疗效比较研究[J].临床合理用药杂志,2019,12(12):77-78.[5]高巍,姚红娟.奥美拉唑联合铝碳酸镁治疗胃溃疡合并胃出血的临床研究[J].山西医药杂志,2020,49(8):1001-1003.[6]樊冬杰,黄玉伟.铝碳酸镁联合四联疗法治疗幽门螺杆菌感染并十二指肠溃疡120例临床观察[J].安徽医药,2020,24(2):393-397.[7]Eisner F,Hermann D,Bajaeifer K,et al.Gastric Ulcer Complications after the Introduction of Proton Pump Inhibitors into Clinical Routine: 20-Year Experience[J].Visceral Medicine,2017,33:221-226.[8]刘宏伟,黄玉洁,杨剑英,等.铝碳酸镁、兰索拉唑、阿莫西林、呋喃唑酮四联疗法治疗幽门螺杆菌相关性胃溃疡的效果及安全性评价[J].中国综合临床,2020,36(1):22-27.[9]Ban H,Inatomi O,Murata M,et al.Vonoprazan vs lansoprazole for the treatment of artificial gastric ulcer after endoscopic submucosal dissection: a prospective randomized comparative study[J].J Clin Biochem Nutr,2021,68(3):259-263.[10]罗炎杰,王晓辉,李宇奇,等.兰索拉唑与奥美拉唑治疗活动期胃溃疡的效果及对血清抗氧化因子的影响[J].现代生物医学进展,2018,18(7):1369-1371.[11]赖人旭,任江南,苟新敏,等.铝碳酸镁片联合埃索美拉唑肠溶片治疗幽门螺杆菌感染合并活动性胃溃疡的临床研究[J].中国临床药理学杂志,2017,33(19):1868-1870.[12]孙晓,孙万日.埃索美拉唑、铝碳酸镁和莫沙比利联合使用在GERD、Hp相关性胃炎中的应用价值[J].热带医学杂志,2018,18(4):519-523.[13]董浩,金世禄,朱凤鸣,等.磷酸铝凝胶联合兰索拉唑对Hp阳性胃溃疡患者HP清除率及血清MMP-9、GAS水平变化的影响[J].中国地方病防治杂志,2017,32(9):1057,1059.[14]杨兴平,李梦元.铝碳酸镁联合艾司奥美拉唑对胃溃疡患者微血管形态及再生黏膜组织的影响[J].现代消化及介入诊疗,2019,24(3):264-267.[15]王佳,温馨,刘梅,等.铝碳酸镁联合艾司奥美拉唑对胃溃疡黏膜组织及微血管形态的影响[J].西部医学,2019,31(12):1939-1942.[16]李鑫.铝碳酸镁联合兰索拉唑与单用兰索拉唑治疗幽门螺杆菌相关性胃溃疡的疗效对比[J].现代消化及介入诊疗,2018,23(2):178-180.[17]杜方杰,刘勇,卢贤敏,等.兰索拉唑三联疗法用于幽门螺杆菌相关性胃溃疡的临床观察[J].中国药房,2017,28(24):3354-3357.[18]梁丽娟,聂爱英,雷超,等.盐酸小檗碱、阿莫西林、兰索拉唑、铋剂四联疗法根除幽门螺杆菌283例的临床研究[J].中华消化杂志,2017,37(3):167-171.[19]Bagheri N,Shirzad H,Elahi S,et al.Downregulated regulatory T cell function is associated with increased peptic ulcer in Helicobacter pylori-infection[J].Microb Pathog,2017,110:165-175.[20]杨瑞琦,毛华,黄丽韫,等.铝碳酸镁联合艾司奥美拉唑治疗胃溃疡黏膜愈合质量的临床研究[J].中华消化杂志,2017,37(1):35-40.[21]李应杰,曹桂芳.磷酸铝凝胶联合兰索拉唑治疗幽门螺杆菌阳性胃溃疡的临床研究[J].现代药物与临床,2017,32(1):67-70.[22]蒋芹,惠雷.消化性溃疡患儿Hp感染与hBD-2、PGⅠ/PGⅡ、Th1/Th2水平的相关性及影响因素分析[J].医学临床研究,2022,39(1):88-90,94.

相似文献/References:

[1]邱梦君,郑国荣.大黄、黄连、黄芩联合三联序贯治疗Hp感染的疗效分析[J].医学信息,2018,31(06):137.[doi:10.3969/j.issn.1006-1959.2018.06.047]
　QIU Meng-jun,ZHENG Guo-rong.Curative Effect Analysis of Sequential Treatment of Hp Infection by Rhubarb,Coptis Chinensis and Radix Scutellariae[J].Journal of Medical Information,2018,31(18):137.[doi:10.3969/j.issn.1006-1959.2018.06.047]
[2]夏 铭,张正坤,曾海龙,等.四种疗法治疗幽门螺杆菌阳性消化性溃疡疗效分析[J].医学信息,2018,31(11):18.[doi:10.3969/j.issn.1006-1959.2018.11.006]
　XIA Ming,ZHANG Zheng-kun,ZENG Hai-long,et al.Therapeutic Effect of Four Kinds of Therapy on Helicobacter Pylori Positive Peptic Ulcer[J].Journal of Medical Information,2018,31(18):18.[doi:10.3969/j.issn.1006-1959.2018.11.006]
[3]薛守宇,廉 婷,耿爱民.补中益气活血方对胃溃疡患者血清TFF2和SOD水平的影响[J].医学信息,2022,35(10):105.[doi:10.3969/j.issn.1006-1959.2022.10.025]
　XUE Shou-yu,LIAN Ting,GENG Ai-min.Effect of Buzhong Yiqi Huoxue Recipe on Serum Levels of TFF2 and SOD in Patients with Gastric Ulcer[J].Journal of Medical Information,2022,35(18):105.[doi:10.3969/j.issn.1006-1959.2022.10.025]
[4]侯拂晓.四联疗法治疗幽门螺旋杆菌相关性十二指肠球炎疗效分析[J].医学信息,2018,31(17):135.[doi:10.3969/j.issn.1006-1959.2018.17.042]
　HOU Fu-xiao.Therapeutic Effect of Quadruple Therapy on Helicobacter pylori Associated Duodenal Inflammation[J].Journal of Medical Information,2018,31(18):135.[doi:10.3969/j.issn.1006-1959.2018.17.042]
[5]潮子健,汪文生,谢宏伟.年龄对胃部常见良性疾病患者的胃蛋白酶原及胃泌素-17水平的影响[J].医学信息,2018,31(23):105.[doi:10.3969/j.issn.1006-1959.2018.23.028]
　CHAO Zi-jian,WANG Wen-sheng,XIE Hong-wei.Effect of Age on Pepsinogen and Gastrin-17 Levels in Patients with Common Benign Diseases of the Stomach[J].Journal of Medical Information,2018,31(18):105.[doi:10.3969/j.issn.1006-1959.2018.23.028]
[6]陈 鹏,吴 楠,葛俊君,等.地衣芽胞杆菌联合幽门螺旋杆菌补救疗法的临床观察[J].医学信息,2018,31(23):114.[doi:10.3969/j.issn.1006-1959.2018.23.031]
　CHEN Peng,WU Nan,GE Jun-jun,et al.Clinical Observation of Bacillus Licheniformis Combined with H.pylori Salvage Therapy[J].Journal of Medical Information,2018,31(18):114.[doi:10.3969/j.issn.1006-1959.2018.23.031]
[7]朱爱娥,王菊艳.系统护理干预对慢性胃炎及胃溃疡患者临床疗效及生活质量的影响研究[J].医学信息,2019,32(04):188.[doi:10.3969/j.issn.1006-1959.2019.04.063]
　ZHU Ai-e,WANG Ju-yan.Effect of Systematic Nursing Intervention on Clinical Efficacy and Quality of Life in Patients with Chronic Gastritis and Stomach Ulcer[J].Journal of Medical Information,2019,32(18):188.[doi:10.3969/j.issn.1006-1959.2019.04.063]
[8]王晓琼,曾凡玲.体检者胃溃疡检出率及其影响因素分析[J].医学信息,2019,32(23):132.[doi:10.3969/j.issn.1006-1959.2019.23.039]
　WANG Xiao-qiong,ZENG Fan-ling.Analysis of the Detection Rate of Gastric Ulcer and its Influencing Factors in Physical Examination Patients[J].Journal of Medical Information,2019,32(18):132.[doi:10.3969/j.issn.1006-1959.2019.23.039]
[9]魏 明.铝碳酸镁与艾司奥美拉唑联合治疗胃溃疡的疗效[J].医学信息,2021,34(21):109.[doi:10.3969/j.issn.1006-1959.2021.21.029]
　WEI Ming.Effect of Magnesium Aluminate Combined with Esomeprazole in the Treatment of Gastric Ulcer[J].Journal of Medical Information,2021,34(18):109.[doi:10.3969/j.issn.1006-1959.2021.21.029]
[10]谢迎新.复方嗜酸乳杆菌联合常规四联疗法治疗幽门螺旋杆菌感染消化性溃疡的疗效[J].医学信息,2020,33(02):138.[doi:10.3969/j.issn.1006-1959.2020.02.040]
　XIE Ying-xin.Effect of Compound Lactobacillus Acidophilus Combined with Conventional Quadruple Therapy in the Treatment of Peptic Ulcer Caused by Helicobacter Pylori Infection[J].Journal of Medical Information,2020,33(18):138.[doi:10.3969/j.issn.1006-1959.2020.02.040]

更新日期/Last Update: 1900-01-01